Update shared on 06 Nov 2025
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation.
What's in the News
- Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference. The trial showed clinically and statistically significant hemoglobin improvements and low rates of adverse events.
- The US FDA has accepted Shield's clinical supplement for ACCRUFeR®/FeRACCRU® and granted Priority Review to extend the indication to adolescents. Approval is anticipated in 2026, with plans to file for even younger populations and an oral liquid pediatric formulation.
- Positive results were published in the European Journal of Heart Failure from the multicenter ORION-HF study. The study found that ferric maltol improved haemoglobin, iron markers, exercise capacity, and quality of life in patients with heart failure and iron deficiency anemia, with no serious adverse events reported.
- Completion of a £1.5 million follow-on equity offering through the issue of 20,000,000 ordinary shares at £0.075 each.
Valuation Changes
- Fair Value Estimate remains unchanged at $0.16.
- Discount Rate has remained virtually stable, now at 6.82% compared to the previous 6.82%.
- Revenue Growth has decreased marginally to 41.83% from 41.89%.
- Net Profit Margin has increased slightly to 24.86% from 24.67%.
- Future P/E Ratio has decreased to 9.00x from 9.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.